Asset Details
Do you wish to reserve the book?
Encapsulated faecal microbiota transfer in young women with anorexia nervosa: an open-label feasibility pilot trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Encapsulated faecal microbiota transfer in young women with anorexia nervosa: an open-label feasibility pilot trial
Do you wish to request the book?
Encapsulated faecal microbiota transfer in young women with anorexia nervosa: an open-label feasibility pilot trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Encapsulated faecal microbiota transfer in young women with anorexia nervosa: an open-label feasibility pilot trial
2025
Overview
Perturbations of the gut microbiome have been associated with anorexia nervosa (AN) suggesting microbiome-modulation treatments, like faecal microbiota transfer (FMT), may offer therapeutic benefits. This open-label feasibility pilot trial evaluated the tolerability and microbiological impact of encapsulated, multi-donor FMT in 18 young women with AN (
Registration: ACTRN12621001504808
). Participants completed clinical and microbiome assessments at enrolment (3 weeks pre-treatment), baseline, and 3, 6, and 12 weeks post-treatment. Fifteen participants completed FMT, and 11 completed the final follow-up. The primary outcome was the change in gut microbiome composition from baseline to 3 weeks compared with natural variation between enrolment and baseline. FMT produced a significantly greater shift post-treatment (mean ± SD Bray–Curtis dissimilarity 0.36 ± 0.11; p = 0.0007), with participants gaining 38 ± 16 new species. Donor-derived strains comprised 41 ± 12% of the microbiome at 3 weeks, with engraftment persisting at 6 and 12 weeks. FMT was generally well tolerated; adverse events were mostly mild to moderate and overlapped with typical AN symptomatology. Monitoring of clinical outcomes supported the safety profile and suggested potential improvements in anxiety and metabolic parameters; however, the small sample and absence of a control arm preclude safety and efficacy inference. Overall, these findings warrant further investigation through randomised controlled trials in AN.
Here, in an open-label pilot trial, the authors show that multi-donor fecal microbiota transfer in young women with anorexia nervosa was well tolerated and led to lasting changes in gut bacteria, supporting further research on microbiome-based treatments.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
